Unilever Raises 2026 Sales Outlook After Strong Q2 Volume Growth 
Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
Tech Stock Positioning Nears Neutral as Investor Rotation Enters Final Phase, Deutsche Bank Says 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
CATL Shares Jump as $5.6 Billion Buyback Signals Confidence in Long-Term Growth 
Seagate Stock Jumps as AI-Fueled Earnings Beat and Strong FY2027 Outlook Impress Investors 
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline 
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue 
Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy 
Sika Raises 2026 Sales Outlook After Strong First-Half Results Beat Expectations 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth 
Galp Shares Fall After Q2 EBITDA Miss Despite Profit Beat and Higher Dividend 
Zabka Shares Drop 10% as Seven & i Abandons Investment Plans 
Nvidia Eyes $250B Guarantee for OpenAI’s Massive Ohio AI Data Center Project 
Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs 
Johnson & Johnson (J&J) will acquire Momenta Pharmaceuticals Inc for about $6.5 billion to boost its portfolio of autoimmune disease treatments.
The deal would give J&J's Janssen unit access to Momenta's experimental therapy, Nipocalimab, already in its late-stage testing for hemolytic anemia, which destroys healthy red blood cells; and also in its mid-stage testing for neuromuscular disease dubbed myasthenia gravis.
Nipocalimab is expected to be approved as a treatment to several conditions.
J&J said Nipocalimab has the potential for peak year sales that could exceed $1 billion
The biotech and pharmaceutical sectors have recently seen 829 deals valued at $62 billion this year, compared with 839 valued at $290 billion in the same period last year.
J&J's acquisition comes just days after French firm Sanofi closed a $3.7 billion deal to acquire Principia Biopharma Inc for autoimmune disease treatments.
Autoimmune treatments have fetched sales worth billions of dollars, with
AbbVie Inc.'s Humira being the global leader in sales.
